

# Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2019 Results And Provides 2020 Guidance

February 19, 2020

LAVAL, Quebec, Feb. 19, 2020 /PRNewswire/ --

- **Fourth-Quarter 2019 Financial Results**

- **Revenues of \$2.224 Billion**
- **GAAP Cash Generated from Operations of \$234 Million**
- **GAAP Net Loss of \$1.516 Billion**
- **Adjusted EBITDA (non-GAAP)<sup>1</sup> of \$898 Million**

- **Full-Year 2019 Financial Results**

- **Revenues of \$8.601 Billion**
- **GAAP Cash Generated from Operations of \$1.501 Billion**
- **GAAP Net Loss of \$1.788 Billion**
- **Adjusted EBITDA (non-GAAP)<sup>1</sup> of \$3.571 Billion**

- **Delivered Total Company Reported Revenue Growth of 5% in the Fourth Quarter and 3% for the Full Year of 2019**

- **Eighth Consecutive Quarter of Total Company Organic Revenue Growth<sup>2</sup>**

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we") today announced its fourth-quarter and full-year 2019 financial results.

"In 2019, we delivered on our 'pivot to offense' strategy. Our fourth-quarter and full-year 2019 results demonstrated the consistency and durability of Bausch Health, as we reported our eighth consecutive quarter of organic revenue growth<sup>2</sup> and our first full year of reported revenue growth since 2015," said Joseph C. Papa, chairman and CEO, Bausch Health. "The Salix and Bausch + Lomb/International segments are leading our resurgence with continued strong performance."

"During the year, we invested in our future by increasing our commitment to R&D and by deploying approximately \$250 million for bolt-on acquisitions to enhance our current product portfolio and add to our development pipeline," Mr. Papa continued.

## Company Highlights

### Executing on Core Businesses and Advancing Pipeline

- The Bausch + Lomb/International segment comprised approximately 55% of the Company's reported revenue in 2019
  - Reported revenue in the Bausch + Lomb/International segment increased by 2% in 2019 compared to 2018; revenue in this segment grew organically<sup>1,2</sup> by 5% compared to 2018, driven by organic growth<sup>1,2</sup> across all five business units
  - Delivered third consecutive year of organic revenue growth<sup>2</sup> in 2019
  - Launched multiple products in 2019, including:
    - Ocuvite® Eye Performance vitamins

- PreserVision® AREDS 2 Formula minigel eye vitamins
- LOTELEX® SM (loteprednol etabonate ophthalmic gel) 0.38%
- Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses
- Zen™ Multifocal scleral lens for Presbyopia
- enVista® toric MX60ET intraocular lens
- Acquired licensing rights for several investigational products, including:
  - XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension), with a proposed indication of treatment for macular edema associated with uveitis
  - NOV03<sup>3</sup> (perfluorohexyloctane), a first-in-class drug with a novel mechanism of action to treat Dry Eye Disease associated with Meibomian gland dysfunction
  - EM-100, an investigational eye drop that, if approved, will be the first over-the-counter preservative-free eye drop for the treatment of itchy eyes associated with allergies
- The Salix segment comprised approximately 23% of the Company's reported revenue in 2019
  - Reported revenue in the Salix segment increased by 16% in 2019 compared to 2018
  - Reported revenue of XIFAXAN® (rifaximin) increased by 22% in 2019 compared to 2018
  - Acquired TRULANCE® (plecanatide), a treatment for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation
  - Acquired dolcanatide, an investigational compound that has demonstrated proof-of-concept in treating patients with multiple gastrointestinal conditions
  - Entered into a licensing agreement with the University of California, Los Angeles to develop and commercialize a novel investigational compound for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
  - Acquired licensing rights for MT-1303 (amiselimod), a late-stage investigational sphingosine 1-phosphate (S1P) modulator for the treatment of inflammatory bowel disease, and conducted study to evaluate its cardiovascular safety
- The Ortho Dermatologics segment comprised approximately 7% of the Company's revenue in 2019
  - Reported revenues in the Global Solta business unit grew by 44% in 2019 compared to 2018, driven by continued strong demand for Thermage® FLX system following the launch in the Asia Pacific region
  - Launched DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, for the topical treatment of plaque psoriasis in adults
  - Launched a cash-pay prescription program, Dermatology.com, and expanded it to all Walgreens U.S. retail pharmacy locations
  - Received approval from the U.S. Food and Drug Administration for ARAZLO™ (tazarotene) Lotion, 0.045%, for the topical treatment of acne vulgaris in patients nine years of age and older; launch is planned for the first half of 2020

### **Strategic Capital Allocation and Debt Management**

- Increased Research and Development (R&D) in 2019 by 14%, or \$58 million, compared to 2018
- Utilized approximately \$1.100 billion in cash generated from operations to repay debt by approximately \$900 million and for 'bolt-on' acquisitions in 2019
- Refinanced \$4.240 billion of debt in 2019 to extend maturities and provide flexibility
- Raised \$1.260 billion of debt in 2019 to fund the settlement of the legacy Valeant U.S. 'stock drop' litigation and pay the related financing fees and expenses

### **Fourth-Quarter and Full-Year 2019 Revenue Performance**

Total reported revenues were \$2.224 billion for the fourth quarter of 2019, as compared to \$2.121 billion in the fourth quarter of 2018, an increase of \$103 million, or 5%.

Total reported revenues were \$8.601 billion for the full year of 2019, as compared to \$8.380 billion for the full year of 2018, an increase of \$221 million, or 3%. Excluding the unfavorable impact of foreign exchange of \$112 million, the impact of a 2019 acquisition of \$55 million and the impact of divestitures and discontinuations of \$54 million, revenue grew organically<sup>1,2</sup> by approximately 4% compared to the full year of 2018, driven by organic growth<sup>1,2</sup> in the Salix and Bausch + Lomb/International segments.

Revenues by segment were as follows:

Fourth-Quarter 2019

<i>(in millions)</i>	<b>Three Months Ended</b>			<b>Change at</b>		
	<b>December 31</b>		<b>Reported</b>	<b>Reported</b>	<b>Constant</b>	<b>Organic</b>
	<b>2019</b>	<b>2018</b>	<b>Change</b>	<b>Change</b>	<b>Currency<sup>4</sup></b>	<b>Change<sup>1,2</sup></b>
Bausch + Lomb/International	\$1,238	\$1,205	\$33	3%	3%	3%
Salix	\$517	\$426	\$91	21%	21%	17%
Ortho Dermatologics	\$158	\$160	(\$2)	(1%)	(1%)	(1%)
Diversified Products	<u>\$311</u>	<u>\$330</u>	(\$19)	(6%)	(6%)	(5%)
Total Revenues	\$2,224	\$2,121	\$103	5%	5%	4%

Full-Year 2019

<i>(in millions)</i>	<b>Twelve Months Ended</b>			<b>Change at</b>		
	<b>December 31</b>		<b>Reported</b>	<b>Reported</b>	<b>Constant</b>	<b>Organic</b>
	<b>2019</b>	<b>2018</b>	<b>Change</b>	<b>Change</b>	<b>Currency<sup>4</sup></b>	<b>Change<sup>1,2</sup></b>
Bausch + Lomb/International	\$4,739	\$4,664	\$75	2%	4%	5%
Salix	\$2,022	\$1,749	\$273	16%	16%	13%
Ortho Dermatologics	\$565	\$617	(\$52)	(8%)	(8%)	(8%)
Diversified Products	<u>\$1,275</u>	<u>\$1,350</u>	(\$75)	(6%)	(6%)	(5%)

Total Revenues	\$8,601	\$8,380	\$221	3%	4%	4%
----------------	---------	---------	-------	----	----	----

## **Bausch + Lomb/International Segment**

Bausch + Lomb/International segment revenues were \$1.238 billion for the fourth quarter of 2019, as compared to \$1.205 billion for the fourth quarter of 2018, an increase of \$33 million, or 3%. Excluding the impact of divestitures and discontinuations of \$6 million, the Bausch + Lomb/International segment grew organically<sup>1,2</sup> by approximately 3% compared to the fourth quarter of 2018, primarily due to growth in the Global Consumer, Global Surgical and Global Vision Care business units.

Bausch + Lomb/International segment revenues were \$4.739 billion for the full year of 2019, as compared to \$4.664 billion for the full year of 2018, an increase of \$75 million, or 2%. Excluding the unfavorable impact of foreign exchange of \$110 million and the impact of divestitures and discontinuations of \$41 million, the Bausch + Lomb/International segment grew organically<sup>1,2</sup> by 5% compared to the full year of 2018, due to organic growth<sup>1,2</sup> across all five business units.

## **Salix Segment**

Salix segment revenues were \$517 million for the fourth quarter of 2019, as compared to \$426 million for the fourth quarter of 2018, an increase of \$91 million, or 21%. The increase was primarily driven by XIFAXAN®, which grew 29% as compared to the fourth quarter of 2018.

Salix segment revenues were \$2.022 billion for the full year of 2019, as compared to \$1.749 billion for the full year of 2018, an increase of \$273 million, or 16%. Growth in the segment was primarily driven by higher sales of XIFAXAN®, which grew 22% as compared to the full year of 2018, partially offset by the loss of exclusivity of products in the segment, primarily UCERIS® (budesonide) and APRISO® (mesalamine), which negatively impacted revenues by \$96 million.

## **Ortho Dermatologics Segment**

Ortho Dermatologics segment revenues were \$158 million for the fourth quarter of 2019, as compared to \$160 million for the fourth quarter of 2018, a decrease of \$2 million, or 1%. The decline was due to lower volumes primarily driven by the loss of exclusivity of ELIDEL® (pimecrolimus) Cream, 1%, ZOVIRAX® (acyclovir) Cream, 5%, and SOLODYN® (minocycline HCl), partially offset by higher revenues in the Global Solta business unit and revenues from new product launches in the Ortho Dermatologics business unit.

Ortho Dermatologics segment revenues were \$565 million for the full year of 2019, as compared to \$617 million for the full year of 2018, a decrease of \$52 million, or 8%. The decline was due to lower volumes primarily driven by the loss of exclusivity of ELIDEL®, ZOVIRAX®, SOLODYN® and ACANYA® (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%, which negatively impacted revenues by \$121 million, and was partially offset by higher revenues in the Global Solta business unit and revenues from new product launches in the Ortho Dermatologics business unit.

## **Diversified Products Segment**

Diversified Products segment revenues were \$311 million for the fourth quarter of 2019, as compared to \$330 million for the fourth quarter of 2018, a decrease of \$19 million, or 6%. Diversified Products segment revenues were \$1.275 billion for the full year of 2019, as compared to \$1.350 billion for the full year of 2018, a decrease of \$75 million, or 6%. The decreases in revenue for both the fourth quarter and full year of 2019 were primarily attributed to the previously reported loss of exclusivity for a basket of products.

## **Operating Results**

Operating loss was \$1.076 billion for the fourth quarter of 2019, as compared to operating

income of \$25 million for the fourth quarter of 2018, a decrease of \$1.101 billion. The decrease in operating results for the fourth quarter of 2019 was primarily driven by the accrual of legal reserves established for the resolution of the legacy Valeant U.S. 'stock drop' litigation, other related actions and ongoing legacy litigation and investigations, partially offset by lower impairments and increased revenues in the fourth quarter of 2019 versus the fourth quarter of 2018.

Operating loss was \$203 million for the full year of 2019, as compared to operating loss of \$2.384 billion for the full year of 2018, a favorable change of \$2.181 billion. The increase in operating results primarily reflects goodwill impairment charges recognized in 2018 of \$2.322 billion, decreases in the amortization and impairments of intangible assets and increased revenues and gross margins in 2019 versus 2018. The increase in operating results was partially offset by the accrual of legal reserves established for the resolution of the legacy Valeant U.S. 'stock drop' litigation, other related actions and ongoing legacy litigation and investigations.

### **Net Loss**

Net loss for the fourth quarter of 2019 was \$1.516 billion, as compared to net loss of \$344 million for the same period in 2018, an unfavorable change of \$1.172 billion. The change is primarily driven by the decrease of \$1.101 billion in operating results as discussed above and higher income taxes, partially offset by lower interest expense and debt extinguishment charges.

Net loss for the full year of 2019 was \$1.788 billion, as compared to net loss of \$4.148 billion for the same period in 2018, a favorable change of \$2.360 billion. The change is primarily driven by the increase of \$2.181 billion in operating results as discussed above and lower interest expense and debt extinguishment charges.

Adjusted net income (non-GAAP)<sup>1</sup> for the fourth quarter of 2019 was \$404 million, as compared to \$368 million for the fourth quarter of 2018, an increase of \$36 million, or 10%.

Adjusted net income (non-GAAP)<sup>1</sup> for the full year of 2019 was \$1.559 billion, as compared to \$1.410 billion for the full year of 2018, an increase of \$149 million, or 11%.

### **Cash Generated from Operations**

The Company generated \$234 million of cash from operations in the fourth quarter of 2019, as compared to \$319 million in the fourth quarter of 2018, a decrease of \$85 million, or 27%. The decrease in cash from operations was primarily attributed to the timing of payments and receipts in the ordinary course of business, partially offset by improved operating results.

The Company generated \$1.501 billion of cash from operations in 2019, which was in line with 2018.

### **EPS**

GAAP Earnings Per Share (EPS) Diluted for the fourth quarter of 2019 was (\$4.30), as compared to (\$0.98) for the fourth quarter of 2018. GAAP EPS Diluted for the full year of 2019 was (\$5.08), as compared to (\$11.81) for the full year of 2018.

### **Adjusted EBITDA (non-GAAP)<sup>1</sup>**

Adjusted EBITDA (non-GAAP)<sup>1</sup> was \$898 million for the fourth quarter of 2019, as compared to \$858 million for the fourth quarter of 2018, an increase of \$40 million, or 5%.

Adjusted EBITDA (non-GAAP)<sup>1</sup> was \$3.571 billion for the full year of 2019, as compared to \$3.474 billion for the full year of 2018, an increase of \$97 million, or 3%. The increase was due to higher revenues, most notably in the Salix segment, which has favorable gross margins,

partially offset by higher operating expenditures to support new product launches and R&D projects.

## 2020 Financial Outlook

Bausch Health provided guidance for the full year of 2020, as follows:

- **Full-Year revenues in the range of \$8.65 – \$8.85 billion**
- **Full-Year Adjusted EBITDA (non-GAAP) in the range of \$3.50 - \$3.65 billion**

Other than with respect to GAAP Revenues, the Company only provides guidance on a non-GAAP basis. The Company does not provide a reconciliation of forward-looking Adjusted EBITDA (non-GAAP) to GAAP net income (loss), due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. In periods where significant acquisitions or divestitures are not expected, the Company believes it might have a basis for forecasting the GAAP equivalent for certain costs, such as amortization, which would otherwise be treated as non-GAAP to calculate projected GAAP net income (loss). However, because other deductions (such as restructuring, gain or loss on extinguishment of debt and litigation and other matters) used to calculate projected net income (loss) vary dramatically based on actual events, the Company is not able to forecast on a GAAP basis with reasonable certainty all deductions needed in order to provide a GAAP calculation of projected net income (loss) at this time. The amount of these deductions may be material and, therefore, could result in projected GAAP net income (loss) being materially less than projected Adjusted EBITDA (non-GAAP). The guidance provided in this section represents forward-looking information and a financial outlook, and actual results may vary. Please see the risks and assumptions referred to in the Forward-looking Statements section of this news release.

## Additional Highlights

- Bausch Health's cash, cash equivalents and restricted cash were \$3.244 billion<sup>5</sup> at Dec. 31, 2019
- The Company's availability under the Revolving Credit Facility was \$1.055 billion at Dec. 31, 2019
- Basic weighted average shares outstanding for the fourth quarter of 2019 were 352.6 million shares. Diluted weighted average shares outstanding for the fourth quarter of 2019 were 359.2 million shares<sup>6</sup>
- Basic weighted average shares outstanding for the full year of 2019 were 352.1 million shares. Diluted weighted average shares outstanding for the full year of 2019 were 357.2 million shares<sup>6</sup>

## Conference Call Details

Date: Wednesday, Feb. 19, 2020

Time: 8:00 a.m. EST

Webcast: <http://ir.bauschhealth.com/events-and-presentations>

Participant Event Dial-in: +1 (888) 317-6003 (United States)  
+1 (412) 317-6061 (International)  
+1 (866) 284-3684 (Canada)

Participant Passcode: 8170812

Replay Dial-in: +1 (877) 344-7529 (United States)  
+1 (412) 317-0088 (International)

## About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at

[www.bauschhealth.com](http://www.bauschhealth.com)

## Forward-looking Statements

This news release contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, Bausch Health's future prospects and performance, including the Company's 2020 full-year guidance. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken, or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements, including the Company's full-year guidance, are based upon the current expectations and beliefs of management and are provided for the purpose of providing additional information about such expectations and beliefs, and readers are cautioned that these statements may not be appropriate for other purposes. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Company's most recent annual and quarterly reports and detailed from time to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including, without limitation, assumptions regarding our 2020 full-year guidance with respect to adjusted SG&A expense (non-GAAP) and the Company's ability to continue to manage such expense in the manner anticipated, the anticipated timing and extent of the Company's R&D expense, the expected timing and impact of loss of exclusivity for certain of our products, expected currency impact based on the exchange rates as of Jan. 31, 2020, expectations regarding gross margin, expectations regarding base performance and management's belief regarding the impact of the coronavirus reported to have surfaced in China on the operations and financial results of the Company, and the assumption that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. Additional information regarding certain of these material factors and assumptions may also be found in the Company's filings described above. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable in the circumstances, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

## Non-GAAP Information

To supplement the financial measures prepared in accordance with U.S. generally accepted

accounting principles (GAAP), the Company uses certain non-GAAP financial measures, including (i) Adjusted EBITDA (non-GAAP), (ii) organic growth/change and (iii) constant currency. As discussed below, we also provide Adjusted Net Income (non-GAAP) to provide supplemental information to readers. Management uses these non-GAAP measures as key metrics in the evaluation of the Company's performance and the consolidated financial results and, in part, in the determination of cash bonuses for its executive officers. The Company believes these non-GAAP measures are useful to investors in their assessment of our operating performance and the valuation of our Company. In addition, these non-GAAP measures address questions the Company routinely receives from analysts and investors, and in order to assure that all investors have access to similar data, the Company has determined that it is appropriate to make this data available to all investors.

However, these measures are not prepared in accordance with GAAP nor do they have any standardized meaning under GAAP. In addition, other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way we calculate such measures. Accordingly, our non-GAAP financial measures may not be comparable to such similarly titled non-GAAP measures. We caution investors not to place undue reliance on such non-GAAP measures, but instead to consider them with the most directly comparable GAAP measures. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. The reconciliations of these historic non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP are shown in the tables below. However, as indicated above, for guidance purposes, the Company does not provide reconciliations of projected Adjusted EBITDA (non-GAAP) to projected GAAP net income (loss), due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations.

### ***Specific Non-GAAP Measures***

#### **Adjusted EBITDA (non-GAAP)**

Adjusted EBITDA (non-GAAP) is GAAP net (loss) income (its most directly comparable GAAP financial measure) adjusted for interest expense, net, provision for (benefit from), income taxes, depreciation and amortization and certain other items, as further described below. Management believes that Adjusted EBITDA (non-GAAP), along with the GAAP measures used by management, most appropriately reflect how the Company measures the business internally and sets operational goals and incentives, especially in light of the Company's new strategies. In particular, the Company believes that Adjusted EBITDA (non-GAAP) focuses management on the Company's underlying operational results and business performance. As a result, the Company uses Adjusted EBITDA (non-GAAP) both to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes Adjusted EBITDA (non-GAAP) is a useful measure to evaluate current performance. Adjusted EBITDA (non-GAAP) is intended to show our unleveraged, pre-tax operating results and therefore reflects our financial performance based on operational factors. In addition, cash bonuses for the Company's executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) targets.

Adjusted EBITDA (non-GAAP) reflects adjustments based on the following items:

- **Restructuring and integration costs**: The Company has incurred restructuring costs as it implemented certain strategies, which involved, among other things, improvements to its infrastructure and operations, internal reorganizations and impacts from the divestiture of assets and businesses. In addition, in connection with its acquisition of certain assets of Synergy Pharmaceuticals Inc. ("Synergy"), the Company has incurred certain severance and integration costs which were not essential to complete, close or report the acquisition. With regard to infrastructure and operational improvements which the Company has taken to improve efficiencies in the businesses and facilities, these tend to be costs intended to right size the business or organization that fluctuate significantly between periods in amount, size and

timing, depending on the improvement project, reorganization or transaction. With regard to the severance and integration costs associated with the acquisition of certain assets of Synergy, these costs are specific to the acquisition itself and provided no benefit to the ongoing operations of the Company. As a result, the Company does not believe that such costs (and their impact) are truly representative of the underlying business. The Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

- Acquired in-process research and development costs: The Company has excluded expenses associated with acquired in-process research and development, as these amounts are inconsistent in amount and frequency and are significantly impacted by the timing, size and nature of acquisitions. Furthermore, as these amounts are associated with research and development acquired, the Company does not believe that they are a representation of the Company's research and development efforts during the period.
- Asset impairments: The Company has excluded the impact of impairments of finite-lived and indefinite-lived intangible assets, as well as impairments of assets held for sale, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions and divestitures. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes intangible impairments from its non-GAAP expenses, the Company believes that it is important for investors to understand that intangible assets contribute to revenue generation.
- Goodwill impairments: The Company has excluded the impact of goodwill impairment. When the Company has made acquisitions where the consideration paid was in excess of the fair value of the net assets acquired, the remaining purchase price is recorded as goodwill. For assets that we developed ourselves, no goodwill is recorded. Goodwill is not amortized but is tested for impairment. In January 2017, new accounting guidance was issued which simplifies the subsequent measurement of an impairment to goodwill. Under the new guidance, which the Company early adopted effective Jan. 1, 2018, the amount of goodwill impairment is measured as the excess of a reporting unit's carrying value over its fair value. Management excludes these charges in measuring the performance of the Company and the business.
- Share-based compensation: The Company has excluded the impact of costs relating to share-based compensation. The Company believes that the exclusion of share-based compensation expense assists investors in the comparisons of operating results to peer companies. Share-based compensation expense can vary significantly based on the timing, size and nature of awards granted.
- Acquisition-related costs and adjustments excluding amortization of intangible assets: The Company has excluded the impact of acquisition-related costs and fair value inventory step-up resulting from acquisitions as the amounts and frequency of such costs and adjustments are not consistent and are significantly impacted by the timing and size of its acquisitions. In addition, the Company has excluded the impact of acquisition-related contingent consideration non-cash adjustments due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to fair value estimates, and the amount and frequency of such adjustments is not consistent and is significantly impacted by the timing and size of the Company's acquisitions, as well as the nature of the agreed-upon consideration.
- Loss on extinguishment of debt: The Company has excluded loss on extinguishment of debt as this represents a cost of refinancing our existing debt and is not a reflection of our operations for the period. Further, the amount and frequency of such charges are not consistent and are significantly impacted by the timing and size of debt financing transactions and other factors in the debt market out of management's control.
- Other Non-GAAP charges: The Company has excluded certain other amounts, including legal and other professional fees incurred in connection with recent legal and governmental

proceedings, investigations and information requests respecting certain of our distribution, marketing, pricing, disclosure and accounting practices, litigation and other matters, and net (gain) loss on sale of assets. In addition, the Company has excluded certain other expenses, such as IT infrastructure investment, that are the result of other, non-comparable events to measure operating performance. These events arise outside of the ordinary course of continuing operations. Given the unique nature of the matters relating to these costs, the Company believes these items are not normal operating expenses. For example, legal settlements and judgments vary significantly, in their nature, size and frequency, and, due to this volatility, the Company believes the costs associated with legal settlements and judgments are not normal operating expenses. In addition, as opposed to more ordinary course matters, the Company considers that each of the recent proceedings, investigations and information requests, given their nature and frequency, are outside of the ordinary course and relate to unique circumstances. The Company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors. However, investors should understand that many of these costs could recur and that companies in our industry often face litigation.

Finally, to the extent not already adjusted for above, Adjusted EBITDA (non-GAAP) reflects adjustments for interest, taxes, depreciation and amortization (EBITDA represents earnings before interest, taxes, depreciation and amortization).

#### Adjusted Net Income (non-GAAP).

Historically, management has used adjusted net income (non-GAAP) (the most directly comparable GAAP financial measure for which is GAAP net income (loss)) for strategic decision making, forecasting future results and evaluating current performance. This non-GAAP measure excludes the impact of certain items (as further described below) that may obscure trends in the Company's underlying performance. By disclosing this non-GAAP measure, it was management's intention to provide investors with a meaningful, supplemental comparison of the Company's operating results and trends for the periods presented. It was management's belief that this measure is also useful to investors as such measure allowed investors to evaluate the Company's performance using the same tools that management had used to evaluate past performance and prospects for future performance. Accordingly, it was the Company's belief that adjusted net income (non-GAAP) was useful to investors in their assessment of the Company's operating performance and the valuation of the Company. It is also noted that, in recent periods, our GAAP net income (loss) was significantly lower than our adjusted net income (non-GAAP). Commencing in 2017, management of the Company identified and began using certain new primary financial performance measures to assess the Company's financial performance. However, management still believes that adjusted net income (non-GAAP) may be useful to investors in their assessment of the Company and its performance.

In addition to certain of the adjustments described above (namely restructuring and integration costs, acquired in-process research and development costs, loss on extinguishment of debt, asset impairments, goodwill impairments, acquisition-related adjustments, excluding amortization, and other non-GAAP charges), adjusted net income (non-GAAP) also reflects adjustments based on the following additional item:

- Amortization of intangible assets: The Company has excluded the impact of amortization of intangible assets, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes amortization of intangible assets from its non-GAAP expenses, the Company believes that it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in the amortization of additional intangible assets.

## Organic Growth/Change

Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of recent acquisitions, divestitures and discontinuations (if applicable). Organic growth/change is change in GAAP Revenue (its most directly comparable GAAP financial measure) adjusted for certain items, as further described below, of businesses that have been owned for one or more years. Organic revenue growth/change is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic growth/change to assess performance of its business units and operating and reportable segments, and the Company in total, without the impact of foreign currency exchange fluctuations and recent acquisitions, divestitures and product discontinuations. The Company believes that such measures are useful to investors as they provide a supplemental period-to-period comparison.

Organic growth/change reflects adjustments for: (i) the impact of period-over-period changes in foreign currency exchange rates on revenues and (ii) the revenues associated with acquisitions, divestitures and discontinuations of businesses divested and/or discontinued. These adjustments are determined as follows:

- Foreign currency exchange rates: Although changes in foreign currency exchange rates are part of our business, they are not within management's control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the business. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.
- Acquisitions, divestitures and discontinuations: In order to present period-over-period organic revenue (non-GAAP) growth/change on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue (non-GAAP) growth/change excludes from the current period, revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue (non-GAAP) growth/change excludes from the prior period (but not the current period), all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period.

## Constant Currency

Changes in the relative values of non-U.S. currencies to the U.S. dollar may affect the Company's financial results and financial position. To assist investors in evaluating the Company's performance, we have adjusted for foreign currency effects. Constant currency impact is determined by comparing 2019 reported amounts adjusted to exclude currency impact, calculated using 2018 monthly average exchange rates, to the actual 2018 reported amounts.

Please also see the reconciliation tables below for further information as to how these non-GAAP measures are calculated for the periods presented.

- 1 Please see the tables at the end of this news release for a reconciliation of this and other non-GAAP measures to the nearest comparable GAAP measure.
- 2 Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of recent acquisitions, divestitures and discontinuations.

3 The acquisition of licensing rights for NOV03 was announced in late 2019, and the upfront payment was made in early 2020.

4 To assist investors in evaluating the Company's performance, we have adjusted for changes in foreign currency exchange rates. Change at constant currency, a non-GAAP metric, is determined by comparing 2019 reported amounts adjusted to exclude currency impact, calculated using 2018 monthly average exchange rates, to the actual 2018 reported amounts.

5 Cash, cash equivalents and restricted cash at Dec. 31, 2019 include net proceeds from the December 2019 \$2.500 billion bond issuance that are intended to be used to finance the \$1.210 billion pending resolution of the legacy Valeant U.S. 'stock drop' litigation due in 2020 and that were used to replace \$1.240 billion of debt due May 2023 on Jan. 16, 2020.

6 Diluted weighted average shares includes the dilutive impact of options and restricted stock units, which are approximately 6,658,000 common shares for the 3 months ended Dec. 31, 2019 and approximately 5,106,000 common shares for the 12 months ended Dec. 31, 2019, and which are excluded when calculating GAAP diluted loss per share because the effect of including the impact would be anti-dilutive.

## FINANCIAL TABLES FOLLOW

**Bausch Health Companies Inc.**

**Table 1**

### Condensed Consolidated Statements of Operations

**For the Three and Twelve Months Ended December 31, 2019  
and 2018**

**(unaudited)**

**Three Months Ended      Twelve Months Ended**

**December 31,      December 31,**

*(in millions)*

**2019      2018      2019      2018**

#### **Revenues**

Product sales	\$ 2,198	\$ 2,098	\$ 8,489	\$ 8,271
---------------	----------	----------	----------	----------

Other revenues	26	23	112	109
----------------	----	----	-----	-----

	2,224	2,121	8,601	8,380
--	-------	-------	-------	-------

#### **Expenses**

Cost of goods sold (excluding amortization and impairments of intangible assets)	622	592	2,297	2,309
Cost of other revenues	13	10	53	42
Selling, general and administrative	668	626	2,554	2,473
Research and development	114	120	471	413
Amortization of intangible assets	445	502	1,897	2,644
Goodwill impairments	—	109	—	2,322
Asset impairments	26	134	75	568
Restructuring and integration costs	3	6	31	22
Acquisition-related contingent consideration	10	14	12	(9)
Other expense (income), net	1,399	(17)	1,414	(20)
	3,300	2,096	8,804	10,764
Operating (loss) income	(1,076)	25	(203)	(2,384)
Interest income	3	2	12	11
Interest expense	(391)	(414)	(1,612)	(1,685)
Loss on extinguishment of debt	(2)	(44)	(42)	(119)
Foreign exchange and other	(4)	5	8	23
Loss before (provision for) benefit from income taxes	(1,470)	(426)	(1,837)	(4,154)
(Provision for) benefit from income taxes	(47)	84	54	10
Net loss	(1,517)	(342)	(1,783)	(4,144)
Net loss (income) attributable to noncontrolling interest	1	(2)	(5)	(4)
<b>Net loss attributable to Bausch Health Companies Inc.</b>	<b>\$ (1,516)</b>	<b>\$ (344)</b>	<b>\$ (1,788)</b>	<b>\$ (4,148)</b>

**Reconciliation of GAAP Net Loss to Adjusted Net Income (non-GAAP)****For the Three and Twelve Months Ended December 31, 2019 and 2018****(unaudited)**

	<b>Three Months Ended</b>		<b>Twelve Months Ended</b>	
	<b>December 31,</b>		<b>December 31,</b>	
<i>(in millions)</i>	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
<b>Net loss attributable to Bausch Health Companies Inc.</b>	<b>\$ (1,516)</b>	<b>\$ (344)</b>	<b>\$ (1,788)</b>	<b>\$ (4,148)</b>
Non-GAAP adjustments: <sup>(a)</sup>				
Amortization of intangible assets	445	502	1,897	2,644
Asset impairments	26	134	75	568
Goodwill impairments	—	109	—	2,322
Restructuring and integration costs	3	6	31	22
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	10	14	25	(9)
Loss on extinguishment of debt	2	44	42	119
Litigation and other matters	1,389	3	1,401	(27)
Acquired in-process research and development costs	32	—	41	1
IT infrastructure investment	9	—	24	—
Legal and other professional fees	13	17	35	52

Net (gain) loss on sale of assets	(21)	(20)	(31)	6
Other	(1)	(1)	(7)	(2)
Tax effect of non-GAAP adjustments	13	(96)	(186)	(138)
Total non-GAAP adjustments	1,920	712	3,347	5,558
<b>Adjusted net income attributable to Bausch Health Companies Inc. (non-GAAP)</b>	<b>\$ 404</b>	<b>\$ 368</b>	<b>\$ 1,559</b>	<b>\$ 1,410</b>

(a) The components of and further details respecting each of these non-GAAP adjustments and the financial statement line item to which each component relates can be found on Table 2a.

### Bausch Health Companies Inc.

**Table 2a**

#### Reconciliation of GAAP to Non-GAAP Financial Information

**For the Three and Twelve Months Ended December 31,  
2019 and 2018**

**(unaudited)**

	<b>Three Months Ended</b>		<b>Twelve Months Ended</b>	
	<b>December 31,</b>	<b>December 31,</b>	<b>2019</b>	<b>2018</b>
<i>(in millions)</i>				

#### **Cost of goods sold reconciliation:**

GAAP Cost of goods sold (excluding amortization and impairments of intangible assets)	\$ 622	\$ 592	\$ 2,297	\$ 2,309
Fair value inventory step-up resulting from acquisitions	—	—	(5)	—

(a)

Adjusted cost of goods sold (excluding amortization and impairments of intangible assets) (non-GAAP)	\$ 622	\$ 592	\$ 2,292	\$ 2,309
--	--------	--------	----------	----------

**Selling, general and administrative reconciliation:**

GAAP Selling, general and administrative	\$ 668	\$ 626	\$ 2,554	\$ 2,473
IT infrastructure investment <sup>(b)</sup>	(9)	—	(24)	—
Legal and other professional fees <sup>(c)</sup>	(13)	(17)	(35)	(52)
Other Selling, general and administrative <sup>(d)</sup>	—	1	2	2
Adjusted selling, general and administrative (non-GAAP)	\$ 646	\$ 610	\$ 2,497	\$ 2,423

**Amortization of intangible assets reconciliation:**

GAAP Amortization of intangible assets	\$ 445	\$ 502	\$ 1,897	\$ 2,644
Amortization of intangible assets <sup>(e)</sup>	(445)	(502)	(1,897)	(2,644)
Adjusted amortization of intangible assets (non-GAAP)	\$ —	\$ —	\$ —	\$ —

**Goodwill impairments reconciliation:**

GAAP Goodwill impairments	\$ —	\$ 109	\$ —	\$ 2,322
Goodwill impairments <sup>(f)</sup>	—	(109)	—	(2,322)
Adjusted goodwill impairments (non-GAAP)	\$ —	\$ —	\$ —	\$ —

**Restructuring and integration costs reconciliation:**

GAAP Restructuring and integration costs	\$ 3	\$ 6	\$ 31	\$ 22
Restructuring and integration costs <sup>(g)</sup>	(3)	(6)	(31)	(22)
Adjusted restructuring and integration costs (non-GAAP)	\$ —	\$ —	\$ —	\$ —

**Asset impairments reconciliation:**

GAAP Asset impairments	\$ 26	\$ 134	\$ 75	\$ 568
Asset impairments <sup>(i)</sup>	(26)	(134)	(75)	(568)
Adjusted asset impairments (non-GAAP)	\$ —	\$ —	\$ —	\$ —

**Acquisition-related contingent consideration reconciliation:**

GAAP Acquisition-related contingent consideration	\$ 10	\$ 14	\$ 12	\$ (9)
Acquisition-related contingent consideration <sup>(a)</sup>	(10)	(14)	(12)	9
Adjusted acquisition-related contingent consideration (non-GAAP)	\$ —	\$ —	\$ —	\$ —

**Bausch Health Companies Inc.**

**Table 2a  
(continued)**

**Reconciliation of GAAP to Non-GAAP Financial Information**

**For the Three and Twelve Months Ended December 31, 2019 and 2018**

**(unaudited)**

	<b>Three Months Ended</b>		<b>Twelve Months Ended</b>	
	<b>December 31,</b>		<b>December 31,</b>	
<i>(in millions)</i>	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>

**Other expense (income), net reconciliation:**

GAAP Other expense (income), net	\$ 1,399	\$ (17)	\$ 1,414	\$ (20)
Net gain (loss) on sale of assets <sup>(j)</sup>	21	20	31	(6)
Litigation and other matters <sup>(k)</sup>	(1,389)	(3)	(1,401)	27

Acquisition-related costs <sup>(a)</sup>	—	—	(8)	—
Acquired in-process research and development costs <sup>(b)</sup>	(32)	—	(41)	(1)
Other <sup>(d)</sup>	1	—	5	—
Adjusted other expense (income) (non-GAAP)	\$ —	\$ —	\$ —	\$ —

**Loss on extinguishment of debt reconciliation:**

GAAP Loss on extinguishment of debt	\$ (2)	\$ (44)	\$ (42)	\$ (119)
Loss on extinguishment of debt <sup>(m)</sup>	2	44	42	119
Adjusted loss on extinguishment of debt (non-GAAP)	\$ —	\$ —	\$ —	\$ —

**(Provision for) benefit from income taxes reconciliation:**

GAAP (Provision for) benefit from income taxes	\$ (47)	\$ 84	\$ 54	\$ 10
Tax effect of non-GAAP adjustments <sup>(n)</sup>	13	(96)	(186)	(138)
Adjusted provision for income taxes (non-GAAP)	\$ (34)	\$ (12)	\$ (132)	\$ (128)

- (a) Represents the three components of the non-GAAP adjustment of "Acquisition-related costs and adjustments (excluding amortization of intangible assets)" (see Table 2).
- (b) Represents the sole component of the non-GAAP adjustment of "IT infrastructure investment" (see Table 2).
- (c) Represents the sole component of the non-GAAP adjustment of "Legal and other professional fees" (see Table 2). Legal and other professional fees incurred during the three and twelve months ended December 31, 2019 and 2018 in connection with recent legal and governmental proceedings, investigations and information requests related to, among other matters, our distribution, marketing, pricing, disclosure and accounting practices.
- (d) Represents the two components of the non-GAAP adjustment of "Other" (see Table 2).
- (e) Represents the sole component of the non-GAAP adjustment of "Amortization of intangible assets" (see Table 2).
- (f) Represents the sole component of the non-GAAP adjustment of "Goodwill impairment" (see Table 2).

- (g) Represents the sole component of the non-GAAP adjustment of "Restructuring and integration costs" (see Table 2).
- (h) Represents the sole component of the non-GAAP adjustment of "Acquired in-process research and development costs" (see Table 2).
- (i) Represents the sole component of the non-GAAP adjustment of "Asset impairments" (see Table 2).
- (j) Represents the sole component of the non-GAAP adjustment of "Net (gain) loss on sale of assets" (see Table 2).
- (k) Represents the sole component of the non-GAAP adjustment of "Litigation and other matters" (see Table 2).
- (l) Represents the sole component of the non-GAAP adjustment of "Acquired in-process research and development costs" (see Table 2).
- (m) Represents the sole component of the non-GAAP adjustment of "Loss on extinguishment of debt" (see Table 2).
- (n) Represents the sole component of the non-GAAP adjustment of "Tax effect of non-GAAP adjustments" (see Table 2).

**Bausch Health Companies Inc.**

**Table 2b**

**Reconciliation of GAAP Net Loss to Adjusted  
EBITDA (non-GAAP)**

**For the Three and Twelve Months  
Ended December 31, 2019 and 2018**

**(unaudited)**

	<b>Three Months Ended</b>		<b>Twelve Months Ended</b>	
	<b>December 31,</b>		<b>December 31,</b>	
<i>(in millions)</i>	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
<b>Net loss attributable to Bausch Health Companies Inc.</b>	<b>\$ (1,516)</b>	<b>\$ (344)</b>	<b>\$ (1,788)</b>	<b>\$ (4,148)</b>
Interest expense, net	388	412	1,600	1,674

Provision for (benefit from) income taxes	47	(84)	(54)	(10)
Depreciation and amortization	492	546	2,075	2,819
<b>EBITDA</b>	<b>(589)</b>	<b>530</b>	<b>1,833</b>	<b>335</b>
Adjustments:				
Asset impairments	26	134	75	568
Goodwill impairments	—	109	—	2,322
Restructuring and integration costs	3	6	31	22
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	10	14	25	(9)
Loss on extinguishment of debt	2	44	42	119
Share-based compensation	25	22	102	87
Other adjustments:				
Litigation and other matters	1,389	3	1,401	(27)
IT infrastructure investment	9	—	24	—
Legal and other professional fees <sup>(a)</sup>	13	17	35	52
Net (gain) loss on sale of assets	(21)	(20)	(31)	6
Acquired in-process research and development costs	32	—	41	1
Other	(1)	(1)	(7)	(2)
<b>Adjusted EBITDA (non-GAAP)</b>	<b>\$ 898</b>	<b>\$ 858</b>	<b>\$ 3,571</b>	<b>\$ 3,474</b>

(a) Legal and other professional fees incurred during the three and twelve months ended December 31, 2019 and 2018 in connection with recent legal and governmental proceedings, investigations and information

requests related to, among other matters, our distribution, marketing, pricing, disclosure and accounting practices.

## **Bausch Health Companies Inc.**

### **Organic Growth (non-GAAP) - by Segment**

**For the Three Months Ended December 31, 2019 and 2018**

**(unaudited)**

#### **Calculation of Organic Revenue for the Three Months**

<i>(in millions)</i>	<b>December 31, 2019</b>			<b>December 31, 2018</b>		
	<b>Revenue as Reported</b>	<b>Changes in Exchange Rates <sup>(a)</sup></b>	<b>Acquisition</b>	<b>Organic Revenue (Non- GAAP) <sup>(b)</sup></b>	<b>Revenue as Reported</b>	<b>Dives- a Disconti-</b>
<b>Bausch + Lomb/International</b>						
Global Vision Care	\$ 210	\$ —	\$ —	\$ 210	\$ 203	\$ —
Global Surgical	193	2	—	195	186	—
Global Consumer Products	390	2	—	392	368	—
Global Ophtho Rx	155	1	—	156	159	—
International Rx	290	(5)	—	285	289	—
<b>Total Bausch + Lomb/International</b>	<b>1,238</b>	<b>—</b>	<b>—</b>	<b>1,238</b>	<b>1,205</b>	<b>—</b>
<b>Salix</b>						
	517	—	(18)	499	426	—

**Ortho  
Dermatologics**

Ortho Dermatologics <sup>(c)</sup>	94	—	—	94	115
Global Solta	64	—	—	64	45
<b>Total Ortho Dermatologics</b>	<b>158</b>	<b>—</b>	<b>—</b>	<b>158</b>	<b>160</b>
<b>Diversified Products</b>					
Neurology and Other	168	—	—	168	186
Generics <sup>(c)</sup>	117	—	—	117	114
Dentistry <sup>(c)</sup>	26	—	—	26	30
<b>Total Diversified Products</b>	<b>311</b>	<b>—</b>	<b>—</b>	<b>311</b>	<b>330</b>
<b>Totals</b>	<b>\$ 2,224</b>	<b>\$ —</b>	<b>\$ (18)</b>	<b>\$ 2,206</b>	<b>\$ 2,121</b>

(a) The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

(b) To supplement the financial measures prepared in accordance with GAAP, the Company uses certain non-GAAP financial measures. For additional information about the Company's use of such non-GAAP financial measures, refer to the body of the news release to which these tables are attached. Organic revenue (non-GAAP) for the three months ended December 31, 2019 is calculated as revenue as reported adjusted for: (i) the impact for changes in exchange rates (previously defined in this news release) and (ii) revenues attributable to acquisitions during the twelve months subsequent to the day of acquisition, as there are no revenues from those businesses included in the comparable prior period. Organic revenue (non-GAAP) for the three months ended December 31, 2018 is calculated as revenue as reported less revenues attributable to divestitures and discontinuances during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period.

(c) Effective in the first quarter of 2019, one product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Generics business unit in the Diversified Products segment and another product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Dentistry business unit in the Diversified Products segment as management believes the products better align with the new respective business units. These changes in product alignment are not material. Prior period presentations of business unit and segment revenues and profits have been conformed to current segment and business unit reporting structures.

## **Bausch Health Companies Inc.**

### **Organic Growth (non-GAAP) - by Segment**

**For the Twelve Months Ended December 31, 2019 and 2018**

**(unaudited)**

#### **Calculation of Organic Revenue for the Twelve Month**

<i>(in millions)</i>	<b>December 31, 2019</b>			<b>December 31, 2018</b>		
	<b>Revenue as Reported</b>	<b>Changes in Exchange Rates <sup>(a)</sup></b>	<b>Acquisition</b>	<b>Organic Revenue (Non- GAAP) <sup>(b)</sup></b>	<b>Revenue as Reported</b>	<b>Diversion as Reported</b>
<b>Bausch + Lomb/International</b>						
Global Vision Care	\$ 848	\$ 18	\$ —	\$ 866	\$ 814	\$ —
Global Surgical	698	22	—	720	698	—
Global Consumer Products	1,455	36	—	1,491	1,421	—
Global Ophtho Rx	638	13	—	651	641	—
International Rx	1,100	21	—	1,121	1,090	—
<b>Total Bausch + Lomb/International</b>	<b>4,739</b>	<b>110</b>	<b>—</b>	<b>4,849</b>	<b>4,664</b>	<b>—</b>

<b>Salix</b>	2,022	—	(55)	1,967	1,749
<b>Ortho Dermatologics</b>					
Ortho Dermatologics <sup>(c)</sup>	371	—	—	371	482
Global Solta	194	2	—	196	135
Total Ortho Dermatologics	565	2	—	567	617
<b>Diversified Products</b>					
Neurology and Other	715	—	—	715	822
Generics <sup>(c)</sup>	459	—	—	459	412
Dentistry <sup>(c)</sup>	101	—	—	101	116
Total Diversified Products	1,275	—	—	1,275	1,350
<b>Totals</b>	<b>\$ 8,601</b>	<b>\$ 112</b>	<b>\$ (55)</b>	<b>\$ 8,658</b>	<b>\$ 8,380</b>

- (a) The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.
- (b) To supplement the financial measures prepared in accordance with GAAP, the Company uses certain non-GAAP financial measures. For additional information about the Company's use of such non-GAAP financial measures, refer to the body of the news release to which these tables are attached. Organic revenue (non-GAAP) for the nine months ended December 31, 2019 is calculated as revenue as reported adjusted for: (i) the impact for changes in exchange rates (previously defined in this news release) and (ii) revenues attributable to acquisitions during the twelve months subsequent to the day of acquisition, as

there are no revenues from those businesses included in the comparable prior period. Organic revenue (non-GAAP) for the nine months ended December 31, 2018 is calculated as revenue as reported less revenues attributable to divestitures and discontinuances during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period.

(c) Effective in the first quarter of 2019, one product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Generics business unit in the Diversified Products segment and another product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Dentistry business unit in the Diversified Products segment as management believes the products better align with the new respective business units. These changes in product alignment are not material. Prior period presentations of business unit and segment revenues and profits have been conformed to current segment and business unit reporting structures.

## Bausch Health Companies Inc.

## Table

### Other Financial Information

(unaudited)

	December 31, 2019	December 31, 2018
(in millions)		
<b>Cash, Cash Equivalents and Restricted Cash</b>		
Cash and cash equivalents <sup>1, 2</sup>	\$ 3,243	\$ 721
Restricted cash	1	2
<b>Cash, cash equivalents and restricted cash</b>	<b>\$ 3,244</b>	<b>\$ 723</b>

### Debt Obligations

#### Senior Secured Credit Facilities:

Revolving Credit Facility	\$ —	\$ 75
Term Loan Facilities	5,025	5,725
Senior Secured Notes	5,451	4,948

Senior Unsecured Notes	15,407	13,545
Other	12	12
<b>Total long-term debt and other, net of premiums, discounts and issuance costs</b>	<b>25,895</b>	<b>24,305</b>
Plus: Unamortized premiums, discounts and issuance costs	293	327
<b>Total long-term debt and other</b>	<b>\$ 26,188</b>	<b>\$ 24,632</b>

### **Maturities and Mandatory Payments of Debt Obligations**

2019	\$ —	\$ 228
2020 <sup>1</sup>	1,240	303
2021	103	1,003
2022	1,553	1,553
2023	2,595	6,348
2024	2,303	2,303
2025	10,632	10,632
2026 - 2030	7,762	2,262
<b>Total debt obligations</b>	<b>\$ 26,188</b>	<b>\$ 24,632</b>

### **Three Months Ended**

**December 31,**

**2019**

**2018**

### **Twelve Months Ended**

**December 31,**

**2019**

**2018**

### **Cash provided by operating activities**

\$ 234

\$ 319

\$ 1,501

\$ 1,501

<sup>1</sup> On December 18, 2019, the Company issued a conditional notice of redemption to redeem \$1,240 million of May 2023 Unsecured Notes on January 16, 2020. On December 30, 2019, the Company completed the December 2019 Financing and Refinancing Transactions, satisfying the condition included in the conditional notice of redemption. On January 16, 2020, the Company repaid \$1,240 million aggregate principal amount of May 2023 Unsecured Notes which were due in 2020 in the table above.

<sup>2</sup> On January 10, 2020, the Company made a payment of \$200 million related to the settlement of the U.S. Securities Litigation.

**Investor Contact:**

Arthur Shannon

[arthur.shannon@bauschhealth.com](mailto:arthur.shannon@bauschhealth.com)

(514) 856-3855

(877) 281-6642 (toll free)

**Media Contact:**

Lainie Keller

[lainie.keller@bauschhealth.com](mailto:lainie.keller@bauschhealth.com)

(908) 927-1198

# BAUSCH Health

C

View original content to download multimedia:

<http://www.prnewswire.com/news-releases/bausch-health-companies-inc-announces-fourth-quarter-and-full-year-2019-results-and-provides-2020-guidance-301007197.html>

SOURCE Bausch Health Companies Inc.

Investor Inquiries

[ir@bauschhealth.com](mailto:ir@bauschhealth.com)



LEGAL NOTICE

PRIVACY POLICY

877-281-6642

514-856-3855 (Canada)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

## Media inquiries

[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com) ©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

**CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION**

